Colonic Perforation After Treatment With Nivolumab in Esophageal Cancer: A Case Report
Annals of Coloproctology
; : S39-S43, 2021.
Artigo
em Inglês
| WPRIM (Pacífico Ocidental)
| ID: wpr-896751
Biblioteca responsável:
WPRO
ABSTRACT
With the advent of checkpoint inhibitors, it has opened up opportunities for numerous cancer patients. However, as is the case with every treatment, complications need to be weighed. Gastrointestinal adverse effects, such as diarrhea and colitis are well-known complications for checkpoint inhibitors. In severe cases, colitis-induced colonic perforation may occur with an estimation of 1.0% to 1.5% in anti-CTLA-4 antibodies. However, only a handful of cases of such devastating complications have been reported in anti-PD-1 antibodies such as pembrolizumab and nivolumab. We here report a case of intestinal perforation in a patient treated with nivolumab.
Texto completo:
Disponível
Contexto em Saúde:
Doenças Negligenciadas
Problema de saúde:
Diarreia
Base de dados:
WPRIM (Pacífico Ocidental)
Idioma:
Inglês
Revista:
Annals of Coloproctology
Ano de publicação:
2021
Tipo de documento:
Artigo